-
Jan 24, 2025 | 
healio.com | Peter Kaiser |Anthony DeFino |Eamon Dreisbach
January 24, 2025 1 min read VIDEO: OTX-TKI moves toward phase 3 trial for treatment of diabetic retinopathy Add topic to email alerts Please provide your email address to receive an email when new articles are posted on Retina/Vitreous in Ophthalmology. Subscribe Added to email alerts You've successfully added Retina/Vitreous in Ophthalmology to your alerts. You will receive an email when new content is published.
-
Nov 11, 2024 | 
healio.com | Peter Kaiser |Anthony DeFino |Eamon Dreisbach
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, ofOcular Therapeutix, discusses the company’s shift to a retina-focused program.
-
Oct 31, 2024 | 
retinalphysician.com | Peter Kaiser
In January 2012, I channeled my inner Steve Jobs to cajole electronic medical record companies to “think different” about the future of EMR. It was my first Upfront as editor-in-chief of Retinal Physician. One hundred and seven Upfronts later, it is with a heavy heart that I announce that this is my last. In January, the new editor in chief, Diana Do, MD, of Byers Eye Institute at Stanford, will take over this enviable position and enlighten us in her unique way as she takes the helm.
-
Oct 1, 2024 | 
retinalphysician.com | Peter Kaiser
This year, both the American Society of Retina Specialists (ASRS) and the Retina Society held their annual meetings across the pond. This is not surprising, because all the societies move their annual meeting to an international location every few years. However, on the rare occasions that the international meetings overlap, as they did this year, most US retina specialists will have to choose which one to attend.
-
Sep 1, 2024 | 
retinalphysician.com | Peter Kaiser
I was at my nephew’s home the other day and watched the kids play College Football 25 by EA Sports. The game was in glorious 4k and the players truly looked alive. The game play was incredible, using plays from the actual college playbooks. It boggles the mind to think how sophisticated the programming behind this game is. Videogames are a $100 billion industry, so I am sure EA Sports spent millions developing the title.
-
Aug 26, 2024 | 
nature.com | Ashish Sharma |Peter Kaiser |Frank G. Holz |Sobha Sivaprasad |Taku Wakabayashi |Nilesh Kumar | +3 more
The majority (95.2%) of the ophthalmologists were aware of all the ranibizumab biosimilars available in India. Biosimilar ranibizumab was the most common ranibizumab administered with 50–100% usage in 51% respondents whereas the proportion of originator usage was below 25% in the majority of practices (62.8%) (Fig. 1B).
-
Jul 24, 2024 | 
modernretina.com | John W. Kitchens |Peter Kaiser
July 24, 2024By John Kitchens, MD, and Peter Kaiser, MD, discuss drug duration, accelerating dosing intervals, and other pearls for aflibercept dosing in wet AMD. In this podcast, John Kitchens, MD, is joined by Peter Kaiser, MD. They discuss higher molar dose and share pearls and their clinical best practices. What are the challenges when treating patients with higher molar doses? How can clinicians help patients transition to a higher dose? Listen and find out today.
-
Jul 22, 2024 | 
europe.ophthalmologytimes.com | John W. Kitchens |Peter Kaiser
July 22, 2024By John Kitchens, MD, is joined by Peter Kaiser, MD, to discuss higher molar dose and its translation into clinical practice. They also discussed the challenges they face in treating patients with higher molar doses, including insurance limitations, safety concerns and convincing insurance carriers to switch to a new dose. They shared clinical pearls for helping patients transition to a higher dose. Increasing aflibercept dose for longer drug duration in eyes.
-
Jul 20, 2024 | 
nature.com | Keean Nanji |Amin Hatamnejad |Mark Phillips |Dena Zeraatkar |Tien Yin Wong |Robyn Guymer | +8 more
The fragility index (FI) of a meta-analysis evaluates the extent that the statistical significance can be changed by modifying the event status of individuals from included trials. Understanding the FI improves the interpretation of the results of meta-analyses and can help to inform changes to clinical practice. This review determined the fragility of ophthalmology-related meta-analyses. Meta-analyses of randomized controlled trials with binary outcomes published in a journal classified as ‘Ophthalmology’ according to the Journal Citation Report or an Ophthalmology-related Cochrane Review were included. An iterative process determined the FI of each meta-analysis. Multivariable linear regression modeling evaluated the relationship between the FI and potential predictive factors in statistically significant and non-significant meta-analyses. 175 meta-analyses were included. The median FI was 6 (Q1–Q3: 3–12). This meant that moving 6 outcomes from one group to another would reverse the study’s findings. The FI was 1 for 18 (10.2%) of the included meta-analyses and was ≤5 for 75 (42.4%) of the included meta-analyses. The number of events (p < 0.001) and the p-value (p < 0.001) were the best predictors of the FI in both significant and non-significant meta-analyses. The statistical significance of meta-analyses in ophthalmology often hinges on the outcome of a few patients. The number of events and the p-value are the most important factors in determining the fragility of the evidence. The FI is an easily interpretable measure that can supplement the reader’s understanding of the strength of the evidence being presented. CRD42022377589
-
Jul 1, 2024 | 
retinalphysician.com | Peter Kaiser
As children, many of us made money as paperboys delivering newspapers on our bicycles to local homes and businesses. It was a set route, which was especially difficult on Sundays when the papers were filled with coupons and extra flyers. Reading the Sunday comics was a weekly highlight. There were minimal other sources of information before the internet.
